Advanced malignant insulinoma. Everolimus response and toxicity

Endocrinol Nutr. 2014 Jan;61(1):e1-3. doi: 10.1016/j.endonu.2013.06.002. Epub 2013 Aug 30.

[Article in English, Spanish]

Authors

Martín Cuesta Hernández¹, Emilia Gómez Hoyos², Clara Marcuello Foncillas², Javier Sastre Valera³, José Ángel Díaz Pérez²

Affiliations

¹ Servicio de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, España. Electronic address: [email protected].
² Servicio de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, España.
³ Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, España.

PMID: 23999009
DOI: 10.1016/j.endonu.2013.06.002

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Compassionate Use Trials
Drug Resistance, Neoplasm
Drug Substitution
Everolimus / adverse effects
Everolimus / therapeutic use*
Fatal Outcome
Humans
Hyperglycemia / chemically induced*
Hypoglycemia / etiology
Insulinoma / drug therapy*
Insulinoma / secondary
Liver Neoplasms / secondary
Male
Middle Aged
Pancreatic Neoplasms / drug therapy*
Pneumonia / chemically induced*

Substances

Everolimus